Home Product PADCEV


Padcev (enfortumab vedotin-ejfv) is an antibody and microtubule inhibitor used to treat bladder and urinary tract cancer(urothelial carcinoma).

PADCEV(Enfortumab Vedotinejfv) is known for the treatment of adult metastatic urothelial cancer patients who come under death receptor-1 (PD-1) or PD-L1 (programmed death-ligand 1) inhibitor, and
platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally
advanced or metastatic setting.


  • Bladder Cancer Treatment.
  • urinary tract Cancer Treatment.

Side effects:

The most common adverse effects are:

  • fatigue.
  • Peripheral.
  • Neuropathy.
  • Decreased appetite.
  • Rash.
  • Alopecia.
  • Nausea.
  • Dysgeusia.
  • Diarrhea.
  • Dry eye.
  • Pruritus.
  • Dry skin.


There are no reviews yet.

Be the first to review “PADCEV”

Your email address will not be published. Required fields are marked *